Kai X. Zhou

Kai X. Zhou

Auto-generated profile, based on publicly available information

Kai X. Zhou

Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai 200032, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2022 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
LZLei Zhu
Lei Zhu
KZKai X. Zhou
Kai X. Zhou
MMMing Z. Ma
Ming Z. Ma
LYLin L. Yao
Lin L. Yao
YZYan-Li Zhang
Yan-Li Zhang
XYXiao-Mei Yang
Xiao-Mei Yang
Hepatocellular carcinoma (HCC) is the most common type of primary liver malignancy with poor prognosis worldwide. Emerging evidences demonstrated critical roles of lipid de novo synthesis in HCC progression, yet its regulatory mechanisms are not fully understood. Herein, we found that tuftelin 1 (TUFT1), an acidic phosphorylated glycoprotein with secretory capacity, was significantly upregulated in HCC and had an excellent correlation with patient survival and malignancy features. Through database mining and experimental validation, we found that TUFT1 was associated with fatty acid metabolism and promoted lipid accumulation in HCC cells. Further, we found that TUFT1 can interact with CREB1, a transcription factor for hepatic lipid metabolism, and regulate its activity and the transcriptions of key enzymes for lipogenesis. TUFT1 promoted HCC cell proliferation significantly, which was partially reversed by treatment of an inhibitor of CREB1, KG-501. Moreover, TUFT1 promoted the capacity of HCC cell invasion in vitro, which was likely mediated by its association with zyxin, a zinc-binding phosphoprotein responsible for the formation of fully mature focal adhesions on extracellular matrix. We found that TUFT1 can interact with ZYX and inhibit its expression and recruitments to focal complexes in HCC cells. Collectively, our study uncovered new regulatory mechanisms of TUFT1-mediated lipogenesis, cell proliferation, and invasion.

1 January 2025 in Stem Cells International
Verified
Journal Article
Open access
KZKaixia Zhou
Kaixia Zhou
XMXiaolu Ma
Xiaolu Ma
TYTianqing Yan
Tianqing Yan
HZHui Zheng
Hui Zheng
SXSuhong Xie
Suhong Xie
RLRenquan Lu
Renquan Lu
Background: Ovarian cancer (OC) stands as the leading cause of cancer‐related deaths among women, globally, owing to metastasis and acquired chemoresistance. Cancer stem cells (CSCs) are accountable for tumor initiation and exhibit resistance to chemotherapy and radiotherapy. Identifying stemness‐related biomarkers that can aid in the stratification of risk and the response to chemotherapy for OC is feasible and critical. Methods: Gene expression and clinical data of patients with OC were downloaded from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database. Four thousand three hundred seventeen stemness‐related genes (SRGs) were acquired from the StemChecker database. TCGA was used as the training dataset, while GSE30161 served as validation dataset. Univariate Cox regression analysis was used to identify overall survival (OS)‐related SRGs, and multivariate Cox regression analysis and random survival forest analysis were used for generating stemness‐relevant prognostic model. Kaplan–Meier plots were used to visualize survival functions. Receiver operating characteristic (ROC) curves were used to assess the prognostic predictive ability of SRG–based features. Associations between signature score, tumor immune phenotype, and response to chemotherapy were analyzed via TIMER 2.0 and oncoPredict R package, respectively. A cohort of Shanghai Cancer Center was employed to verify the predictive robustness of the signature with respect to chemotherapy response. Results: Seven SRGs (actin‐binding Rho activating C‐terminal like (ABRACL), growth factor receptor bound protein 7 (GRB7), Lin‐28 homolog B (LIN28B), lipolysis stimulated lipoprotein receptor (LSR), neuromedin U (NMU), Solute Carrier Family 4 Member 11 (SLC4A11), and thymocyte selection associated family member 2 (THEMIS2)) were found to have excellent predictive potential for patient survival. Patients in the high stemness risk group presented a poorer prognosis ( p < 0.0001), and patients with lower stemness scores were more likely to benefit from chemotherapy. Several tumorigenesis pathways, such as mitotic spindle and glycolysis, were enriched in the high stemness risk group. Tumor with high‐risk scores tended to be in a status of relatively high tumor infiltration of CD4+ T cells, neutrophils, and macrophages, while tumor with low‐risk scores tended to be in a status of relatively high tumor infiltration of CD8+ T cells. Conclusions: The stemness‐relevant prognostic gene signature has the potential to serve as a clinically helpful biomarker for guiding the management of OC patients.

26 October 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
XMXiaolu Ma
Xiaolu Ma
LHLing Hu
Ling Hu
LYLin Yang
Lin Yang
KZKaixia Zhou
Kaixia Zhou
TYTianqing Yan
Tianqing Yan
RLRenquan Lu
Renquan Lu
Rapid progression is considered the major contributor to the poor prognosis of epithelial ovarian cancer (EOC), while the underlying mechanism remains elusive. Herein, we identified that Calpain-5 (CAPN5), a well-known protease, was significantly downregulated across various types of EOC, and acted as a protective indicator for prognosis. Phenotypically, CAPN5 overexpression greatly restrained the proliferation and invasion of EOC, but induced apoptosis, while knocking down CAPN5 exerted opposite effects. Moreover, CAPN5 markedly inhibited epithelial-to-mesenchymal transition (EMT). Mechanistically, CAPN5 exerted its inhibitory effect mainly via downregulating STIP1, a well-recognized oncoprotein in EOC, evidenced by that silencing STIP1 could almost abolish the promotional effects of CAPN5 knockdown on EOC progression. Further experiments demonstrated that CAPN5 catalyzes STIP1 cleavage at R160 residue, exposing the novel Asn-initiated N-terminal fragment of STIP1, which triggered the Arg/N-degron pathway to mediate the K169 ubiquitination of STIP1 fragment by the ATE1-UBR4 cascade. Consequently, the ubiquitinated STIP1 fragment underwent proteasomal degradation. Notably, applying an approved HSP90i, Pimitespib, can effectively suppress CAPN5-low/STIP1-high EOC progression and exert a synergetic effect with Cisplatin. In summary, CAPN5 is a novel suppressor in EOC by acting as an initiator for the N-degron pathway to induce STIP1 degradation, and a CAPN5 low -STIP1 high status served as an indicator to guide Pimitespib application.